Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.41 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.38 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5073662 | 0.78 | DHFR (0.38) | ALDH1A1HPGDCSNK2A1TLR7TLR8 | |
| SCHEMBL5335436 | 0.77 | TLR7 (0.50) | ALDH1A1HPGDTLR7TLR8QTRT1 | |
| SCHEMBL787142 | 0.77 | QTRT1 (0.51) | ALDH1A1HPGDTLR7TLR8QTRT1 | |
| SCHEMBL6809083 | 0.75 | PARP1 (0.41) | TLR7TLR8 | |
| SCHEMBL212367 | 0.75 | ADORA2A (0.45) | TLR7TLR8QTRT1ADORA3ADORA2A | |
| SCHEMBL8600371 | 0.74 | TNKS2 (0.53) | ALDH1A1TLR7TLR8ADORA3ADORA2A | |
| SCHEMBL202971 | 0.74 | ALDH1A1 (0.41) | ALDH1A1HPGDCSNK2A1PTGS1PTGS2 | |
| SCHEMBL9036182 | 0.71 | TLR7 (0.52) | ALDH1A1HPGDTLR7TLR8ADORA3 | |
| SCHEMBL212373 | 0.71 | TLR8 (0.46) | TLR7TLR8ADORA2AELANE | |
| SCHEMBL28350684 | 0.71 | HPGD (0.41) | ALDH1A1HPGDCSNK2A1PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948173-B1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2013-07-17 | — | — | EP | disclosed |
| US-8377957-B2 | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120071463-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY | 2012-03-22 | — | — | US | disclosed |
| US-8088790-B2 | Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090221556-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221556-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | IFNG, IL2, IRF3 | ALDH1A1 517/4885HPGD 123/4885CSNK2A1 1472/4885 |
| US-20120071463-A1 | HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS | IFNG, IL2, IRF3 | ALDH1A1 517/4885HPGD 123/4885CSNK2A1 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.